Key facts
- This page summarizes Scott L. Burrows's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Mar 2023, 15:29.
Scott L. Burrows - 06 Mar 2023 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ARQT
- Reported as of
- 06 Mar 2023
- Net transaction value
- -$4,442
- SEC form
- 4
- Accepted by SEC
- 08 Mar 2023, 15:29:15 UTC
- Prior SEC filing
- 06 Mar 2023
- Next SEC filing
- 05 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Scott L. Burrows
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Scott L. Burrows filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 08 Mar 2023.
Change
- Previous filing in this sequence was filed on 06 Mar 2023.
- Current net transaction value: -$4,442.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARQT
transaction
Common Stock
Sale
- Transaction value
- $4,442
- Shares
- -291
- Change %
- -0.49%
- Price
- $15.26
- Shares after
- 59,115
- Date
- 06 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
Footnote F2
The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.